Project documents | Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Guidance | NICE

Documents

Documents created during the development process.

Invitation to participate

Final scope 2022 reissue (PDF 214 KB)

Published:

19 August 2022
Final stakeholder list 2022 reissue (PDF 169 KB)

Published:

19 August 2022
NICE's response to comments on the draft scope and provisional stakeholder list 2022 reissue (PDF 370 KB)

Published:

19 August 2022
Equality impact assessment (Scoping) 2022 reissue (PDF 123 KB)

Published:

19 August 2022

Invitation to participate

Final scope (PDF 233 KB)

Published:

01 December 2021
Final stakeholder list (PDF 169 KB)

Published:

01 December 2021
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 374 KB)

Published:

01 December 2021
Equality impact assessment (Scoping) (PDF 121 KB)

Published:

01 December 2021

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Draft scope post referral (PDF 250 KB)

Published:

28 October 2021
Draft matrix post referral (PDF 171 KB)

Published:

28 October 2021